{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T15:19:55Z","timestamp":1793200795258,"version":"4.5.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007202","name":"Gouvernement du Canada | Instituts de Recherche en Sant\u00e9 du Canada | CIHR Skin Research Training Centre","doi-asserted-by":"publisher","award":["PJT-156006"],"award-info":[{"award-number":["PJT-156006"]}],"id":[{"id":"10.13039\/501100007202","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Genomic Applications Partnership Proposal (GAPP) grant: \u201cNanoString nCounter Vantage 3D Platform-based Complementary Diagnostic Tests for Precision Medicine in Pediatric Cancers\u201d."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    With the success of immunotherapy in cancer, understanding the tumor immune microenvironment (TIME) has become increasingly important; however in pediatric brain tumors this remains poorly characterized. Accordingly, we developed a clinical immune-oncology gene expression assay and used it to profile a diverse range of 1382 samples with detailed clinical and molecular annotation. In low-grade gliomas we identify distinct patterns of immune activation with prognostic significance in\n                    <jats:italic>BRAF<\/jats:italic>\n                    V600E-mutant tumors. In high-grade gliomas, we observe immune activation and T-cell infiltrates in tumors that have historically been considered immune cold, as well as genomic correlates of inflammation levels. In mismatch repair deficient high-grade gliomas, we find that high tumor inflammation signature is a significant predictor of response to immune checkpoint inhibition, and demonstrate the potential for multimodal biomarkers to improve treatment stratification. Importantly, while overall patterns of immune activation are observed for histologically and genetically defined tumor types, there is significant variability within each entity, indicating that the TIME must be evaluated as an independent feature from diagnosis. In sum, in addition to the histology and molecular profile, this work underscores the importance of reporting on the TIME as an essential axis of cancer diagnosis in the era of personalized medicine.\n                  <\/jats:p>","DOI":"10.1038\/s41467-024-49595-1","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T07:02:50Z","timestamp":1720594970000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Immuno-oncologic profiling of pediatric brain tumors reveals major clinical significance of the tumor immune microenvironment"],"prefix":"10.1038","volume":"15","author":[{"given":"Adrian B.","family":"Levine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liana","family":"Nobre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anirban","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Milos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4844-261X","authenticated-orcid":false,"given":"Nicholas R.","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Stengs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Ryall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Ku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansuba","family":"Rana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Laxer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javal","family":"Sheth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie-Grace","family":"Sbergio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Fedor\u00e1kov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6557-895X","authenticated-orcid":false,"given":"Vijay","family":"Ramaswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4146-1511","authenticated-orcid":false,"given":"Julie","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2013-9467","authenticated-orcid":false,"given":"Robert","family":"Siddaway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5019-2683","authenticated-orcid":false,"given":"Uri","family":"Tabori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2618-4402","authenticated-orcid":false,"given":"Cynthia","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,10]]},"reference":[{"key":"49595_CR1","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41568-020-0285-7","volume":"20","author":"D Bruni","year":"2020","unstructured":"Bruni, D., Angell, H. K. & Galon, J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat. Rev. Cancer 20, 662\u2013680 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"49595_CR2","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/S0140-6736(18)30789-X","volume":"391","author":"F Pag\u00e8s","year":"2018","unstructured":"Pag\u00e8s, F. et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet 391, 2128\u20132139 (2018).","journal-title":"Lancet"},{"key":"49595_CR3","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar3593","volume":"362","author":"R Cristescu","year":"2018","unstructured":"Cristescu, R. et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 362, eaar3593 (2018).","journal-title":"Science"},{"key":"49595_CR4","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cell.2021.01.002","volume":"184","author":"K Litchfield","year":"2021","unstructured":"Litchfield, K. et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell 184, 596\u2013614.e14 (2021).","journal-title":"Cell"},{"key":"49595_CR5","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","volume":"39","author":"A Bagaev","year":"2021","unstructured":"Bagaev, A. et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell 39, 845\u2013865.e7 (2021).","journal-title":"Cancer Cell"},{"key":"49595_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s43018-021-00319-0","volume":"3","author":"EI Hwang","year":"2022","unstructured":"Hwang, E. I. et al. The current landscape of immunotherapy for pediatric brain tumors. Nat. Cancer 3, 11\u201324 (2022).","journal-title":"Nat. Cancer"},{"key":"49595_CR7","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1200\/JCO.2016.66.6552","volume":"34","author":"E Bouffet","year":"2016","unstructured":"Bouffet, E. et al. Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. J. Clin. Oncol. 34, 2206\u20132211 (2016).","journal-title":"J. Clin. Oncol."},{"key":"49595_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41591-021-01581-6","volume":"28","author":"A Das","year":"2022","unstructured":"Das, A. et al. Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. Nat. Med. 28, 125\u2013135 (2022).","journal-title":"Nat. Med."},{"key":"49595_CR9","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/j.cell.2020.05.007","volume":"181","author":"F Klemm","year":"2020","unstructured":"Klemm, F. et al. Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells. Cell 181, 1643\u20131660.e17 (2020).","journal-title":"Cell"},{"key":"49595_CR10","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.cell.2020.04.055","volume":"181","author":"E Friebel","year":"2020","unstructured":"Friebel, E. et al. Single-cell mapping of human brain cancer reveals tumor-specific instruction of tissue-invading leukocytes. Cell 181, 1626\u20131642.e20 (2020).","journal-title":"Cell"},{"key":"49595_CR11","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.cell.2020.08.022","volume":"183","author":"KR Parker","year":"2020","unstructured":"Parker, K. R. et al. Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies. Cell 183, 126\u2013142.e17 (2020).","journal-title":"Cell"},{"key":"49595_CR12","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41571-021-00518-9","volume":"18","author":"M Ott","year":"2021","unstructured":"Ott, M., Prins, R. M. & Heimberger, A. B. The immune landscape of common CNS malignancies: implications for immunotherapy. Nat. Rev. Clin. Oncol. 18, 729\u2013744 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"49595_CR13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41568-019-0224-7","volume":"20","author":"JH Sampson","year":"2020","unstructured":"Sampson, J. H., Gunn, M. D., Fecci, P. E. & Ashley, D. M. Brain immunology and immunotherapy in brain tumours. Nat. Rev. Cancer 20, 12\u201325 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"49595_CR14","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s41593-020-00789-y","volume":"24","author":"AR Pombo Antunes","year":"2021","unstructured":"Pombo Antunes, A. R. et al. Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization. Nat. Neurosci. 24, 595\u2013610 (2021).","journal-title":"Nat. Neurosci."},{"key":"49595_CR15","doi-asserted-by":"publisher","first-page":"4880","DOI":"10.4049\/jimmunol.1301966","volume":"191","author":"AM Griesinger","year":"2013","unstructured":"Griesinger, A. M. et al. Characterization of distinct immunophenotypes across pediatric brain tumor types. J. Immunol. 191, 4880\u20134888 (2013).","journal-title":"J. Immunol."},{"key":"49595_CR16","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s11060-017-2737-9","volume":"137","author":"AS Plant","year":"2018","unstructured":"Plant, A. S. et al. Immunophenotyping of pediatric brain tumors: correlating immune infiltrate with histology, mutational load, and survival and assessing clonal T cell response. J. Neurooncol. 137, 269\u2013278 (2018).","journal-title":"J. Neurooncol."},{"key":"49595_CR17","doi-asserted-by":"publisher","first-page":"e001066","DOI":"10.1136\/jitc-2020-001066","volume":"8","author":"MH Robinson","year":"2020","unstructured":"Robinson, M. H. et al. Subtype and grade-dependent spatial heterogeneity of T-cell infiltration in pediatric glioma. J. Immunother. Cancer 8, e001066 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"49595_CR18","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41591-018-0263-8","volume":"25","author":"F D\u2019Angelo","year":"2019","unstructured":"D\u2019Angelo, F. et al. The molecular landscape of glioma in patients with Neurofibromatosis 1. Nat. Med. 25, 176\u2013187 (2019).","journal-title":"Nat. Med."},{"key":"49595_CR19","doi-asserted-by":"crossref","unstructured":"Persson, M. L. et al. The intrinsic and microenvironmental features of diffuse midline glioma; implications for the development of effective immunotherapeutic treatment strategies. Neuro. Oncol. 24, 1408\u20131422 (2022).","DOI":"10.1093\/neuonc\/noac117"},{"key":"49595_CR20","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/neuonc\/noy145","volume":"21","author":"NAP Lieberman","year":"2018","unstructured":"Lieberman, N. A. P. et al. Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy. Neuro. Oncol. 21, 83\u201394 (2018).","journal-title":"Neuro. Oncol."},{"key":"49595_CR21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40478-018-0553-x","volume":"6","author":"GL Lin","year":"2018","unstructured":"Lin, G. L. et al. Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma. Acta Neuropathol. Commun. 6, 51 (2018).","journal-title":"Acta Neuropathol. Commun."},{"key":"49595_CR22","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/neup.12594","volume":"39","author":"P Jha","year":"2019","unstructured":"Jha, P. et al. Analysis of PD-L1 expression and T cell infiltration in different molecular subgroups of diffuse midline gliomas. Neuropathology 39, 413\u2013424 (2019).","journal-title":"Neuropathology"},{"key":"49595_CR23","doi-asserted-by":"publisher","first-page":"100340","DOI":"10.1016\/j.xgen.2023.100340","volume":"3","author":"JA Shapiro","year":"2023","unstructured":"Shapiro, J. A. et al. OpenPBTA: the open pediatric brain tumor atlas. Cell Genom. 3, 100340 (2023).","journal-title":"Cell Genom."},{"key":"49595_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19015-1","volume":"11","author":"F Avila Cobos","year":"2020","unstructured":"Avila Cobos, F., Alquicira-Hernandez, J., Powell, J. E. & Mestdagh, P. & De Preter, K. Benchmarking of cell type deconvolution pipelines for transcriptomics data. Nat. Commun. 11, 5650 (2020).","journal-title":"Nat. Commun."},{"key":"49595_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18070-y","volume":"11","author":"Y Grabovska","year":"2020","unstructured":"Grabovska, Y. et al. Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunity. Nat. Commun. 11, 4324 (2020).","journal-title":"Nat. Commun."},{"key":"49595_CR26","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi, H. A. et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N. Engl. J. Med. 386, 24\u201334 (2022).","journal-title":"N. Engl. J. Med."},{"key":"49595_CR27","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","volume":"23","author":"BC Cho","year":"2022","unstructured":"Cho, B. C. et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol. 23, 781\u2013792 (2022).","journal-title":"Lancet Oncol."},{"key":"49595_CR28","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1093\/neuonc\/noaa077","volume":"22","author":"K Fukuoka","year":"2020","unstructured":"Fukuoka, K. et al. Clinical impact of combined epigenetic and molecular analysis of pediatric low-grade gliomas. Neuro. Oncol. 22, 1474\u20131483 (2020).","journal-title":"Neuro. Oncol."},{"key":"49595_CR29","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s40425-018-0367-1","volume":"6","author":"P Danaher","year":"2018","unstructured":"Danaher, P. et al. Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA). J. Immunother. Cancer 6, 63 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"49595_CR30","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1200\/JCO.2018.78.2276","volume":"37","author":"PA Ott","year":"2019","unstructured":"Ott, P. A. et al. T-cell\u2013inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J. Clin. Oncol. 37, 318\u2013327 (2019).","journal-title":"J. Clin. Oncol."},{"key":"49595_CR31","doi-asserted-by":"publisher","first-page":"e1462430","DOI":"10.1080\/2162402X.2018.1462430","volume":"7","author":"M Bockmayr","year":"2018","unstructured":"Bockmayr, M. et al. Subgroup-specific immune and stromal microenvironment in medulloblastoma. Oncoimmunology 7, e1462430 (2018).","journal-title":"Oncoimmunology"},{"key":"49595_CR32","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/s41591-020-0821-8","volume":"26","author":"J Theruvath","year":"2020","unstructured":"Theruvath, J. et al. Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid\/rhabdoid tumors. Nat. Med. 26, 712\u2013719 (2020).","journal-title":"Nat. Med."},{"key":"49595_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02391-6","volume":"9","author":"M Schubert","year":"2018","unstructured":"Schubert, M. et al. Perturbation-response genes reveal signaling footprints in cancer gene expression. Nat. Commun. 9, 20 (2018).","journal-title":"Nat. Commun."},{"key":"49595_CR34","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41591-019-0349-y","volume":"25","author":"J Zhao","year":"2019","unstructured":"Zhao, J. et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat. Med. 25, 462\u2013469 (2019).","journal-title":"Nat. Med."},{"key":"49595_CR35","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41586-023-05940-w","volume":"617","author":"JS Bergholz","year":"2023","unstructured":"Bergholz, J. S. et al. PI3K\u03b2 controls immune evasion in PTEN-deficient breast tumours. Nature 617, 139\u2013146 (2023).","journal-title":"Nature"},{"key":"49595_CR36","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","volume":"6","author":"W Peng","year":"2016","unstructured":"Peng, W. et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 6, 202\u2013216 (2016).","journal-title":"Cancer Discov."},{"key":"49595_CR37","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1093\/neuonc\/nox054","volume":"19","author":"AS Berghoff","year":"2017","unstructured":"Berghoff, A. S. et al. Correlation of immune phenotype with IDH mutation in diffuse glioma. Neuro. Oncol. 19, 1460\u20131468 (2017).","journal-title":"Neuro. Oncol."},{"key":"49595_CR38","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40478-022-01323-w","volume":"10","author":"B Mehani","year":"2022","unstructured":"Mehani, B. et al. Immune cell gene expression signatures in diffuse glioma are associated with IDH mutation status, patient outcome and malignant cell state, and highlight the importance of specific cell subsets in glioma biology. Acta Neuropathol. Commun. 10, 19 (2022).","journal-title":"Acta Neuropathol. Commun."},{"key":"49595_CR39","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1126\/science.abj5104","volume":"377","author":"G Notarangelo","year":"2022","unstructured":"Notarangelo, G. et al. Oncometabolite d-2HG alters T cell metabolism to impair CD8+ T cell function. Science 377, 1519\u20131529 (2022).","journal-title":"Science"},{"key":"49595_CR40","doi-asserted-by":"crossref","unstructured":"Ellison, D. W., Hawkins, C. & Jones, D. T. W. cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAF V600E mutation. Acta Neuropahol. 137, 683\u2013687 (2019).","DOI":"10.1007\/s00401-019-01987-0"},{"key":"49595_CR41","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","volume":"25","author":"RG Majzner","year":"2019","unstructured":"Majzner, R. G. et al. CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin. Cancer Res. 25, 2560\u20132574 (2019).","journal-title":"Clin. Cancer Res."},{"key":"49595_CR42","doi-asserted-by":"publisher","first-page":"103453","DOI":"10.1016\/j.ebiom.2021.103453","volume":"69","author":"G Price","year":"2021","unstructured":"Price, G., Bouras, A., Hambardzumyan, D. & Hadjipanayis, C. G. Current knowledge on the immune microenvironment and emerging immunotherapies in diffuse midline glioma. EBioMedicine 69, 103453 (2021).","journal-title":"EBioMedicine"},{"key":"49595_CR43","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1158\/1535-7163.MCT-14-0290","volume":"13","author":"KM Ilieva","year":"2014","unstructured":"Ilieva, K. M. et al. Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma. Mol. Cancer Ther. 13, 2769\u20132783 (2014).","journal-title":"Mol. Cancer Ther."},{"key":"49595_CR44","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1172\/JCI98689","volume":"128","author":"JR Veatch","year":"2018","unstructured":"Veatch, J. R. et al. Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanoma. J. Clin. Invest. 128, 1563\u20131568 (2018). 4.","journal-title":"J. Clin. Invest."},{"key":"49595_CR45","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1470-2045(17)30516-8","volume":"18","author":"S Turajlic","year":"2017","unstructured":"Turajlic, S. et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol. 18, 1009\u20131021 (2017).","journal-title":"Lancet Oncol."},{"key":"49595_CR46","doi-asserted-by":"publisher","first-page":"E7759","DOI":"10.1073\/pnas.1609376113","volume":"113","author":"S Spranger","year":"2016","unstructured":"Spranger, S. et al. Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma. Proc. Natl Acad. Sci. Usa. 113, E7759\u2013E7768 (2016).","journal-title":"Proc. Natl Acad. Sci. Usa."},{"key":"49595_CR47","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/s43018-022-00382-1","volume":"3","author":"V Anagnostou","year":"2022","unstructured":"Anagnostou, V., Bardelli, A., Chan, T. A. & Turajlic, S. The status of tumor mutational burden and immunotherapy. Nat. Cancer 3, 652\u2013656 (2022).","journal-title":"Nat. Cancer"},{"key":"49595_CR48","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein, R. M. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 51, 202\u2013206 (2019).","journal-title":"Nat. Genet."},{"key":"49595_CR49","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41591-018-0339-5","volume":"25","author":"KA Schalper","year":"2019","unstructured":"Schalper, K. A. et al. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nat. Med. 25, 470\u2013476 (2019).","journal-title":"Nat. Med."},{"key":"49595_CR50","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","volume":"25","author":"TF Cloughesy","year":"2019","unstructured":"Cloughesy, T. F. et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat. Med. 25, 477\u2013486 (2019).","journal-title":"Nat. Med."},{"key":"49595_CR51","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers, M. et al. IFN-\u03b3-related mRNA profile predicts clinical response to PD-1. blockade. J. Clin. Invest. 127, 2930\u20132940 (2017).","journal-title":"blockade. J. Clin. Invest."},{"key":"49595_CR52","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.ccell.2018.04.004","volume":"33","author":"A Mackay","year":"2018","unstructured":"Mackay, A. et al. Molecular, pathological, radiological, and immune profiling of non-brainstem pediatric high-grade glioma from the HERBY phase II randomized trial. Cancer Cell 33, 829\u2013842.e5 (2018).","journal-title":"Cancer Cell"},{"key":"49595_CR53","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.ccell.2020.03.011","volume":"37","author":"S Ryall","year":"2020","unstructured":"Ryall, S. et al. Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas. Cancer Cell 37, 569\u2013583.e5 (2020).","journal-title":"Cancer Cell"},{"key":"49595_CR54","unstructured":"Nobre, L. et al. Outcomes of BRAF V600E pediatric gliomas treated with targeted BRAF inhibition. JCO Precis. Oncol. 4 (2020)."},{"key":"49595_CR55","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40478-020-00902-z","volume":"8","author":"S Ryall","year":"2020","unstructured":"Ryall, S., Tabori, U. & Hawkins, C. Pediatric low-grade glioma in the era of molecular diagnostics. Acta Neuropathol. Commun. 8, 30 (2020).","journal-title":"Acta Neuropathol. Commun."},{"key":"49595_CR56","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1056\/NEJMoa2303815","volume":"389","author":"E Bouffet","year":"2023","unstructured":"Bouffet, E. et al. Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations. N. Engl. J. Med. 389, 1108\u20131120 (2023).","journal-title":"N. Engl. J. Med."},{"key":"49595_CR57","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","volume":"14","author":"JJ Luke","year":"2017","unstructured":"Luke, J. J., Flaherty, K. T., Ribas, A. & Long, G. V. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat. Rev. Clin. Oncol. 14, 463\u2013482 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"49595_CR58","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1038\/s43018-021-00260-2","volume":"2","author":"VA Arrieta","year":"2021","unstructured":"Arrieta, V. A. et al. ERK1\/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. Nat. Cancer 2, 1372\u20131386 (2021).","journal-title":"Nat. Cancer"},{"key":"49595_CR59","first-page":"1426","volume":"5","author":"T Larkin","year":"2021","unstructured":"Larkin, T. et al. Upfront adjuvant immunotherapy of replication repair-deficient pediatric glioblastoma with chemoradiation-sparing approach. JCO Precis. Oncol 5, 1426\u20131431 (2021).","journal-title":"Oncol"},{"key":"49595_CR60","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","volume":"6","author":"DA Reardon","year":"2020","unstructured":"Reardon, D. A. et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the checkmate 143 phase 3 randomized clinical trial. JAMA Oncol. 6, 1003\u20131010 (2020).","journal-title":"JAMA Oncol."},{"key":"49595_CR61","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","volume":"19","author":"L Kraehenbuehl","year":"2022","unstructured":"Kraehenbuehl, L., Weng, C.-H., Eghbali, S., Wolchok, J. D. & Merghoub, T. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nat. Rev. Clin. Oncol. 19, 37\u201350 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"49595_CR62","doi-asserted-by":"crossref","unstructured":"Louis, D. N. et al. The 2021 WHO classification of tumors of the Central Nervous System: a summary. Neuro. Oncol. 23, 1231\u20131251 (2021).","DOI":"10.1093\/neuonc\/noab106"},{"key":"49595_CR63","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/ng.2936","volume":"46","author":"P Buczkowicz","year":"2014","unstructured":"Buczkowicz, P. et al. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat. Genet. 46, 451\u2013456 (2014).","journal-title":"Nat. Genet."},{"key":"49595_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-022-28253-4","volume":"13","author":"R Siddaway","year":"2022","unstructured":"Siddaway, R. et al. Splicing is an alternate oncogenic pathway activation mechanism in glioma. Nat. Commun. 13, 1\u201314 (2022).","journal-title":"Nat. Commun."},{"key":"49595_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-19972-7","volume":"11","author":"S Pajovic","year":"2020","unstructured":"Pajovic, S. et al. Epigenetic activation of a RAS\/MYC axis in H3.3K27M-driven cancer. Nat. Commun. 11, 1\u201316 (2020).","journal-title":"Nat. Commun."},{"key":"49595_CR66","doi-asserted-by":"publisher","first-page":"4770","DOI":"10.1158\/1078-0432.CCR-23-0411","volume":"29","author":"A Das","year":"2023","unstructured":"Das, A. et al. Efficacy of nivolumab in pediatric cancers with high mutation burden and mismatch repair deficiency. Clin. Cancer Res. 29, 4770\u20134783 (2023).","journal-title":"Clin. Cancer Res."},{"key":"49595_CR67","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1158\/2159-8290.CD-23-0559","volume":"14","author":"A Das","year":"2024","unstructured":"Das, A. et al. Combined immunotherapy improves outcome for replication-repair-deficient (RRD) high-grade glioma failing anti\u2013PD-1 monotherapy: A report from the international RRD consortium. Cancer Discov. 14, 258\u2013273 (2024).","journal-title":"Cancer Discov."},{"key":"49595_CR68","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40425-015-0088-7","volume":"3","author":"A Cesano","year":"2015","unstructured":"Cesano, A. nCounter(\u00ae) PanCancer Immune Profiling Panel (NanoString Technologies, Inc., Seattle, WA). J. Immunother. Cancer 3, 42 (2015).","journal-title":"J. Immunother. Cancer"},{"key":"49595_CR69","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","volume":"32","author":"Z Gu","year":"2016","unstructured":"Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32, 2847\u20132849 (2016).","journal-title":"Bioinformatics"},{"key":"49595_CR70","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/bioinformatics\/btq170","volume":"26","author":"MD Wilkerson","year":"2010","unstructured":"Wilkerson, M. D. & Hayes, D. N. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 26, 1572\u20131573 (2010).","journal-title":"Bioinformatics"},{"key":"49595_CR71","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","volume":"18","author":"DB Doroshow","year":"2021","unstructured":"Doroshow, D. B. et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat. Rev. Clin. Oncol. 18, 345\u2013362 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"49595_CR72","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nbt.2514","volume":"31","author":"K Cibulskis","year":"2013","unstructured":"Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213\u2013219 (2013).","journal-title":"Nat. Biotechnol."},{"key":"49595_CR73","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/nar\/29.1.308","volume":"29","author":"ST Sherry","year":"2001","unstructured":"Sherry, S. T. et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 29, 308\u2013311 (2001).","journal-title":"Nucleic Acids Res."},{"key":"49595_CR74","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297\u20131303 (2010).","journal-title":"Genome Res."},{"key":"49595_CR75","doi-asserted-by":"publisher","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","volume":"46","author":"MJ Landrum","year":"2018","unstructured":"Landrum, M. J. et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 46, D1062\u2013D1067 (2018).","journal-title":"Nucleic Acids Res."},{"key":"49595_CR76","doi-asserted-by":"publisher","first-page":"D941","DOI":"10.1093\/nar\/gky1015","volume":"47","author":"JG Tate","year":"2019","unstructured":"Tate, J. G. et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 47, D941\u2013D947 (2019).","journal-title":"Nucleic Acids Res."},{"key":"49595_CR77","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1101\/gr.257246.119","volume":"31","author":"S Uhrig","year":"2021","unstructured":"Uhrig, S. et al. Accurate and efficient detection of gene fusions from RNA sequencing data. Genome Res. 31, 448\u2013460 (2021).","journal-title":"Genome Res."},{"key":"49595_CR78","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 14, 7 (2013).","journal-title":"BMC Bioinform."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-49595-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-49595-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-49595-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T11:02:01Z","timestamp":1720868521000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-49595-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,10]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["49595"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-49595-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2655807\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,10]]},"assertion":[{"value":"14 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5790"}}